4.7 Article

Efficiency of GnRH-Loaded Chitosan Nanoparticles for Inducing LH Secretion and Fertile Ovulations in Protocols for Artificial Insemination in Rabbit Does

Journal

ANIMALS
Volume 11, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/ani11020440

Keywords

artificial-insemination; GnRH; nanotechnology; ovulation; rabbit

Ask authors/readers for more resources

Gonadotropin-releasing hormone (GnRH)-loaded chitosan nanoparticles (GnRH-ChNPs) were used to induce ovulation in rabbits for artificial insemination. The use of GnRH-ChNPs reduced the intramuscular GnRH dose by half without compromising fertility, but adding them to semen extenders had negative impacts. Further studies are needed to explore this point and make adjustments.
Simple Summary Nano-drug delivery systems can be employed for improving ovulation induction prior to artificial insemination (AI) in rabbits. In this study, different routes of administration and different doses of GnRH-loaded chitosan nanoparticles (GnRH-ChNPs) were assessed for inducing ovulation in rabbits, proving their usefulness to reduce the GnRH dose and animal handling and improving AI outcomes. The use of GnRH-ChNPs allows for the reduction of the conventional intramuscular GnRH dose to half without compromising fertility. However, the addition of GnRH-ChNPs to semen extenders, although successfully inducing ovulation, has negative impacts on fertility. Thus, more studies are needed to allow further adjustments. Gonadotropin-releasing hormone (GnRH)-loaded chitosan nanoparticles (GnRH-ChNPs) were used at different doses and routes of administration to induce ovulation in rabbits as an attempt to improve artificial insemination (AI) procedures and outcomes. In this study, the characteristics (size, polydispersity, loading efficiency, and zeta-potential) of GnRH-ChNPs and the GnRH release pattern were determined in an in vitro study. A first in vivo study assessed the pituitary and ovarian response to different GnRH-ChNPs doses and routes of administration (two i.m. doses, Group HM = 0.4 mu g and Group QM = 0.2 mu g, and two intravaginal doses, Group HV = 4 mu g and Group QV = 2 mu g) against a control group (C) receiving bare GnRH (0.8 mu g). The HM, QM, and HV treatments induced an earlier LH-surge (90 min) than that observed in group C (120 min), whilst the QV treatment failed to induce such LH surge. The number of ovulation points was similar among treatments, except for the QV treatment (no ovulation points). A second in vivo study was consequently developed to determine the hormonal (progesterone, P-4, and estradiol, E-2) profile and pregnancy outcomes of both HM and HV treatments against group C. The treatment HM, but not the treatment HV, showed adequate P-4 and E-2 concentrations, conception and parturition rates, litter size, litter weight, and viability rate at birth. Overall, the use of GnRH-ChNPs allows for a reduction in the conventional intramuscular GnRH dose to half without compromising fertility. However, the addition of GnRH-ChNPs to semen extenders, although successfully inducing ovulation, has negative impacts on fertility. Thus, more studies are needed to explore this point and allow further adjustments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available